-
Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A, Wright A, Syngelaki A, Maritsa VA, Bardani E, Nicolaides KH.
Ultrasound Obstet Gynecol 2020;56:408-415. pdf -
Analysis of Cell-Free DNA in Maternal Blood in Screening For Aneuploidies: Updated Meta-Analysis.
Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:302-314. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf -
Replacing the combined test by cell-free DNA testing in screening for trisomies 21, 18 and 13: impact on the diagnosis of other chromosomal abnormalities.
Syngelaki A, Pergament E, Homfray T, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:174-84. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester markers of aneuploidy in women positive for HIV.
Savvidou M, Samuel I, Syngelaki A, Poulton M, Nicolaides K.
BJOG 2011;118:844-8. -
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011;31:58-65. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing.
Chen EZ, Chiu RW, Sun H, Akolekar R, Chan KC, Leung TY, Jiang P, Zheng YW, Lun FM, Chan LY, Jin Y, Go AT, Lau ET, To WW, Leung WC, Tang RY, Au-Yeung SK, Lam H, Kung YY, Zhang X, van Vugt JM, Minekawa R, Tang MH, Wang J, Oudejans CB, Lau TK, Nicolaides KH, Lo YM.
PLoS One 2011;6:21791. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection.
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, Gerovassili A, Jin Y, Nicolaides KH, Cantor CR, Ding C.
Nat Med 2007;13:218-23. -
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13(+6) weeks of gestation.
Kagan KO, Frisova V, Nicolaides KH, Spencer K.
Prenat Diagn 2007;27:849-53. -
Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?
Gerovassili A, Garner C, Nicolaides KH, Thein SL, Rees DC.
Prenat Diagn 2007;27:104-10.